Soleno Therapeutics INC Form 4 insider transactions

Soleno Therapeutics' Chief Business Officer, Kevin Norrett, was granted 14,286 restricted stock units and 64,286 employee stock options, aligning executive incentives with future company performance.

Soleno Therapeutics' Chief Development Officer, Manher Joshi, was granted 16,071 restricted stock units and options to purchase 72,321 shares of common stock.

Soleno Therapeutics Director Mark W. Hahn was granted 10,046 restricted stock units, vesting over three years, aligning his interests with shareholders.

Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics, sold 3,830 shares of common stock for $82.76 per share on July 1, 2025, under a Rule 10b5-1 trading plan.

Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc., exercised stock options and sold an equal number of shares, while also reporting a significant adjustment to her beneficial ownership.

Solenos Therapeutics director Birgitte Volck was granted 3,991 Restricted Stock Units (RSUs) on June 5, 2025, as part of her compensation, aligning her interests with shareholders.

Andrew Sinclair, a Director at Soleno Therapeutics Inc., was granted 3,991 Restricted Stock Units (RSUs) on June 5, 2025, as part of his compensation, aligning his interests with long-term shareholder value.

Matthew Pauls, a Director at Soleno Therapeutics Inc. (SLNO), was granted 3,991 restricted stock units (RSUs) as part of his compensation, increasing his total beneficial ownership to 10,491 shares.

Soleno Therapeutics Inc. Director William G. Harris was granted 3,991 restricted stock units (RSUs) on June 5, 2025, as part of his compensation, aligning his interests with shareholders.

SOLENO THERAPEUTICS INC Director Dawn Carter Bir was granted 3,991 restricted stock units (RSUs) on June 5, 2025, increasing her beneficial ownership to 16,991 shares.

Patricia C. Hirano, a Senior Vice President at Soleno Therapeutics, sold 3,782 shares of common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Matthew Pauls of Soleno Therapeutics reports the acquisition and disposal of common stock and derivative securities.

Kristen Yen, SVP at Soleno Therapeutics, reports selling shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, sold shares of common stock on March 27, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

James Mackaness, CFO of Soleno Therapeutics, reports the sale of common stock to cover tax obligations and the exercise of employee stock options.

Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics Inc., sold shares of common stock on March 27, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Patricia Hirano, a Senior Vice President at Soleno Therapeutics, reported the sale of common stock to cover tax obligations and the exercise of employee stock options.

Anish Bhatnagar, CEO of Soleno Therapeutics, reports multiple sales of common stock on March 27, 2025, primarily to cover tax withholding obligations related to vesting restricted stock units, while also exercising stock options.

Vivo Opportunity, LLC, a 10% owner of Soleno Therapeutics Inc, reports selling shares of common stock over three days in March 2025.

Kristen Yen, a Senior Vice President at Soleno Therapeutics, reports the acquisition of common stock and stock options.

Meredith Manning, Chief Commercial Officer of Soleno Therapeutics, reports the acquisition of common stock and stock options.

James Mackaness, CFO of Soleno Therapeutics, reports the acquisition of common stock and stock options.

Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics Inc., reports acquisition of common stock and stock options.

Patricia Hirano, a Senior Vice President at Soleno Therapeutics, reports the acquisition of restricted stock units and stock options.

Anish Bhatnagar, CEO of Soleno Therapeutics, reports the acquisition of restricted stock units and stock options.

A Soleno Therapeutics executive sold shares to cover tax obligations related to vesting restricted stock units.

Solen Therapeutics' Chief Financial Officer, James Mackaness, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

A Soleno Therapeutics executive, Patricia C Hirano, sold shares to cover tax obligations related to vesting restricted stock units.

Solen Therapeutics CEO, Anish Bhatnagar, sold shares of common stock to cover tax obligations related to vesting restricted stock units.

Kristen Yen, a Senior Vice President at Soleno Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.